截至2025年9月末，重庆辖区境内上市公司达78家，较2021年初净增20家，上市公司总市值突破1.25万亿元，较2020年末增长28.87%。 内容来源 | 上海证券报 "十四五"期间，重庆证监局深入贯彻落实党中央相关决策部署，坚持服务实体经济、防范金融风险、深化改革开放，推动辖区上市公司实现数量与质 量"双提升"，为重庆经济社会高质量发展注入强劲动能。 随着新质生产力成为区域发展的核心抓手，各地正加速抢占这一战略高地。重庆这座内陆山城正以资本为杠杆，撬动一场静水深流的结构性革命。截至 2025年9月末，重庆辖区境内上市公司达78家，较2021年初的58家净增20家，覆盖上交所主板、科创板，深交所主板、创业板及北交所各板块。上市公司 总市值突破1.25万亿元，较2020年末增长28.87%。更值得关注的是，营收总额、研发投入、税收贡献等核心指标均实现跨越式提升：研发投入五年间激增 127.45%，有效专利数增长133.93%，税收贡献达495.82亿元，带动就业36.31万人。 这份成绩的背后，不仅是重庆资本市场从规模追赶到质量突围的深层跃迁，更是中国西部在新发展格局下，以资本为纽带重构创新生态、破解发展瓶 ...

"十四五"期间，重庆证监局深入贯彻落实党中央相关决策部署，坚持服务实体经济、防范金融风险、深 化改革开放，推动辖区上市公司实现数量与质量"双提升"，为重庆经济社会高质量发展注入强劲动能。 随着新质生产力成为区域发展的核心抓手，各地正加速抢占这一战略高地。重庆这座内陆山城正以资本 为杠杆，撬动一场静水深流的结构性革命。截至2025年9月末，重庆辖区境内上市公司达78家，较2021 年初的58家净增20家，覆盖上交所主板、科创板，深交所主板、创业板及北交所各板块。上市公司总市 值突破1.25万亿元，较2020年末增长28.87%。更值得关注的是，营收总额、研发投入、税收贡献等核心 指标均实现跨越式提升：研发投入五年间激增127.45%，有效专利数增长133.93%，税收贡献达495.82亿 元，带动就业36.31万人。 这份成绩的背后，不仅是重庆资本市场从规模追赶到质量突围的深层跃迁，更是中国西部在新发展格局 下，以资本为纽带重构创新生态、破解发展瓶颈的生动实践。近日，上海证券报记者深入多家代表性企 业，探寻重庆上市公司在国家战略引领下，以创新驱动与绿色转型书写新时代的高质量发展答卷。 制度创新破解"内陆困局" ...

Core Insights - The Chongqing Private Economy Innovation and Development Conference recognized Zhifei Biological Products Co., Ltd. for its outstanding performance in technological innovation, ranking 3rd in the "2025 Chongqing Private Enterprises Technology Innovation Index Top 100" and 4th in the "2025 Chongqing Private Enterprises R&D Investment Top 50" [1][3] Group 1: Company Achievements - Zhifei Biological has made significant advancements in its R&D projects, particularly in the preventive field, with two vaccines, including a quadrivalent influenza virus split vaccine, launched this year [2] - The company has 34 self-developed projects in the preventive field, with 24 in the application, clinical, or listing application stages [2] - In the therapeutic area, Zhifei has 8 self-developed projects, with 7 in clinical or registration stages, including liraglutide injection awaiting listing application [2] Group 2: R&D Investment and Strategy - Over the past three years, Zhifei Biological has invested more than 6 billion yuan in R&D, reflecting its strong commitment to understanding market demands and technological trends [1][2] - The company follows an innovation strategy of prioritizing independent R&D, supplemented by collaborative R&D and investment incubation, which has laid a solid foundation for its sustainable development [1] Group 3: Future Outlook - Zhifei Biological aims to strengthen its position as an innovation leader, focusing on core technologies and addressing public health needs to contribute to the high-quality development of the biopharmaceutical industry and the construction of a healthy China [3]

在预防领域，智飞生物自主研发的四价流感病毒裂解疫苗、流感病毒裂解疫苗已于今年上市，并在多个省份完成准入；冻干人用狂犬病疫苗（人二倍体细 胞）、ACYW135群脑膜炎球菌多糖结合疫苗、15价肺炎球菌结合疫苗已进入上市审评阶段；四价重组诺如病毒疫苗（毕赤酵母）、福氏宋内氏痢疾双价结 合疫苗等已进入Ⅲ期临床试验阶段；26价肺炎结合疫苗已于澳大利亚及国内开展临床试验。 12月26日，由重庆市工商联主办的重庆市民营经济创新发展大会成功举行，会上正式发布《2025重庆民营企业科技创新指数100强榜单》。智飞生物凭借在 科技创新领域的突出表现，荣登"2025重庆民营企业科技创新指数100强榜单"第3位、"2025重庆民营企业研发投入50家榜单"第4位。智飞生物总裁蒋凌峰出 席会议并代表企业获颁奖牌。 来源：重庆市民营经济创新发展大会主办方 生物医药产业是关系国计民生和国家安全的战略性新兴产业，科技创新是其可持续发展的核心动力。智飞生物自成立以来，始终坚持"自主研发为主、合作 研发为辅、投资孵化为补"的创新策略，持续加大研发投入，深化管线布局，近三年智飞体系累计研发投入超60亿元，自主创新能力得到持续夯实与提升。 今年以来， ...

12月15日，重庆市新闻发布中心举行新闻发布会，介绍了重庆国际生物城创新药产业生态圈建设最新进 展及下一步发展计划。 截至目前，重庆市在研创新药100余个，进入临床试验阶段有42个，其中重庆国 际生物城在研创新药就有56个，进入临床试验阶段有20个，占全市总量的半壁江山，成为全市创新药研 发的核心策源地。 今年以来，重庆市明确提出"加快建设重庆国际生物城创新药产业生态圈"的目标，并出台《重庆市全链 条支持创新药高质量发展若干措施》，精准赋能创新药从实验室研发、临床研究、产业化生产、市场准 入到最终应用的全生命周期。 12月7日，重庆国际生物城入驻企业重庆智翔金泰生物制药股份有限公司研发生产的1类创新药——赛立 奇单抗注射液，成功纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，标志着重 庆1类创新药进医保实现"零的突破"。 此外，重庆坚持以会聚势、以链招商、以才兴业，高水平举办重庆国际人才交流大会·生命科学产业人 才发展大会、生物医学新技术论坛暨技术许可转化活动等系列活动，搭建起链接全球创新资源、高端人 才与产业资本的桥梁。数据显示，今年1月至11月，重庆国际生物城累计签约入库项目21个，协 ...

Group 1: National Medical Insurance Drug List Update - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List will be released on December 7, 2023, adding 114 new drugs, including 50 innovative Class 1 drugs [2] - The first Commercial Health Insurance Innovative Drug List will also be released on the same day, including 19 drugs, such as CAR-T and Alzheimer's treatment drugs [2] - The new drug list will officially take effect on January 1, 2026 [2] Group 2: Company Announcements - 15 A-share pharmaceutical companies announced that their products were included in the new drug list, with many innovative drug companies benefiting [2] - Zai Lab announced that its self-developed drug, Gilteritinib, was included in the National Medical Insurance Drug List, which is expected to enhance sales and market promotion [2] - Junshi Biosciences, ZhiXiang JinTai, and Elysium also had products included in the list, with Junshi's products gaining new indications and being classified under Category B of the National Medical Insurance [3] Group 3: Sales Impact - Heng Rui Medicine stated that the total sales of the newly included drugs for 2024 are estimated to be approximately 8.66 billion yuan, with 7.55 billion yuan expected for the first three quarters of 2025 [4] - The inclusion of these drugs in the National Medical Insurance Drug List is anticipated to positively impact sales, although the exact effect on operating performance is currently uncertain [4]

Group 1: Core Insights - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List was released on December 7, 2023, adding 114 new drugs, including 50 innovative drugs [1] - A new Commercial Health Insurance Innovative Drug List was also published, including 19 drugs, such as CAR-T therapies and Alzheimer's disease treatments [1] - The updated drug list will take effect on January 1, 2026 [1] Group 2: Company Announcements - On December 7, 15 A-share pharmaceutical companies announced that their products were included in the new drug list, particularly many innovative drug companies [2] - Zai Lab announced that its self-developed drug, Jikaxitinib, was included in the National Medical Insurance Drug List, which is expected to enhance sales and market accessibility [2] - Junshi Biosciences and other innovative drug companies also had products included, with Junshi's products gaining new indications in the National Medical Insurance List [2][3] Group 3: Market Impact - Heng Rui Medicine reported that the total sales of its newly included drugs are estimated to be approximately 8.66 billion yuan for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [3] - The inclusion of these drugs in the National Medical Insurance List is expected to positively impact sales and long-term business development for the companies involved [2][3]

Core Points - The National Healthcare Security Administration announced the 2025 National Medical Insurance Drug List, which will take effect on January 1, 2026, adding 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are either unavailable or can be replaced by better alternatives [2][4] Group 1: Drug List Adjustments - The total number of drugs in the directory has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [2][4] - The 2025 adjustment marks the 8th update since the establishment of the National Healthcare Security Administration [7] Group 2: Company Announcements - 15 A-share pharmaceutical companies announced that their products have been included in the new directory, with many innovative drug companies benefiting from this inclusion [4] - Zai Lab's drug, Jikaxitinib, has been included in the directory, which is expected to enhance sales and improve patient accessibility [4] - Junshi Biosciences reported that its products, including Toripalimab and an additional indication for another drug, have been successfully included in the directory [4] - Innovent Biologics' drug, IBI301, has also been added to the new directory, marking a significant milestone for the company [5] - Leading A-share pharmaceutical companies like Fosun Pharma, East China Pharmaceutical, and Heng Rui Medicine have also had several products included, with Heng Rui reporting a combined sales figure of approximately 8.66 billion yuan for the newly added drugs in 2024 [6][7]

Core Viewpoint - The 2025 National Medical Insurance Drug List has been announced, including 114 new drugs, with a focus on innovative drugs and significant improvements in coverage for key areas such as oncology and chronic diseases [4][9]. Group 1: Drug List Adjustments - The 2025 National Medical Insurance Drug List will be implemented on January 1, 2026, with a total of 3,253 drugs, including 1,857 Western medicines and 1,396 traditional Chinese medicines [4]. - The list includes 50 first-class innovative drugs and removes 29 drugs that are either not clinically available or can be replaced by better alternatives [4]. Group 2: Impact on A-Share Companies - 15 A-share pharmaceutical companies announced that their products were included in the new drug list, particularly benefiting innovative drug companies [6]. - Zai Lab's drug, Jikaxitinib, was included, which is used for treating specific types of myelofibrosis, enhancing its market accessibility and sales potential [6]. - Junshi Biosciences reported that its products, including Toripalimab and Oncorine, were added to the list, with all four of its commercialized products now covered [6]. Group 3: Major Pharmaceutical Companies - Leading A-share pharmaceutical companies like Fosun Pharma, Hengrui Medicine, and others have also had products included in the new list, with Hengrui having 10 drugs added and several others with new indications [7]. - Hengrui's drugs are projected to generate approximately 8.66 billion yuan in sales for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [8]. Group 4: Complementary Innovations - In addition to the basic medical insurance list, 19 drugs have been added to the first version of the commercial insurance innovative drug list, including treatments for rare diseases and Alzheimer's, providing a complementary framework to the basic insurance [9].

Core Viewpoint - The 2025 National Medical Insurance Drug List has been released, adding 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are no longer clinically available or can be replaced by better alternatives [2][5]. Group 1: New Additions to the Drug List - A total of 15 A-share pharmaceutical companies announced that their products have been included in the new drug list, particularly benefiting many innovative drug companies [5]. - Zai Lab's drug, Jikaxitinib, has been included in the National Medical Insurance Drug List, which is expected to enhance sales and improve patient accessibility [5][6]. - Junshi Biosciences has added two new indications for its drug, Toripalimab, and successfully included another drug, Oncorine, in the Class B category of the National Medical Insurance List [5]. Group 2: Impact on Major Pharmaceutical Companies - Leading A-share pharmaceutical companies such as Fosun Pharma, East China Pharmaceutical, and Hengrui Medicine have also had products included in the National Medical Insurance List [7]. - Hengrui Medicine has 10 drugs newly added to the list, with a total sales revenue of approximately 8.66 billion yuan in 2024 and about 7.55 billion yuan in the first three quarters of 2025 [8]. - The inclusion of these drugs in the National Medical Insurance List is expected to positively impact sales, although the exact effect on operating performance is currently uncertain [8]. Group 3: Overall Changes in the Drug List - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [2]. - This adjustment marks the 8th update since the establishment of the National Medical Insurance Bureau, indicating ongoing efforts to enhance drug accessibility and affordability [8].